You license to monetise your technology. So, how can you ensure you receive those payments in full? Are licensees really dishonest? We will look at the provisions you should be including to protect yourself. We will also look at how to approach those provisions which your licensee may want to include to limit its payments. We will discuss what the approach to licensing Covid technologies has been. We will also touch on what the courts have had to say about some important provisions in Licence Agreements. Our licence should leave you neither shaken nor stirred.
You may also like
Developing new anti-infective drugs: challenges and opportunities
We will discuss the challenges encountered in developing and commercialising new antibacterial drug compounds for treating drug-resistant pathogens, the opportunities provided by governmental initiatives to incentivise their development, how IP strategies can be optimised to respond to these challenges and opportunities and the very different challenges of developing anti-viral drugs in a post-Covid world.
The TARDIS of trade marks: time, space and strategy
Tuesday 2nd February
This session examines the trade mark factors that need to be considered if a product is to be launched urgently and concerning a product’s ‘space’ – where it sits in the market – and how they affect brand protection strategy.
Plausibility, polymorphs and purity
Plausibility, polymorphs and purity have been recurring themes in the EPO’s Board of Appeal decisions. These topics can underpin a pharmaceutical company’s filing and life cycle management strategy. The EPO’s decisions have been mixed and, in the last year, the Boards have yet again pronounced on these topics in a number of decisions. We will review and discuss the key features of these decisions.